Trial Information
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724